GOG 0252.
Trial name or title | GOG 0252 |
Methods | Study duration: projected to complete in 2016 Type of trial: US multicentre RCT Planned follow‐up duration: 5 years Patients are stratified according to disease stage and size of residual disease after initial staging/debulking surgery |
Participants | Patients with FIGO stage II ‐ IV (no gross residual disease vs gross residual disease with lesion ≤ 1 cm vs any gross residual disease with lesion > 1 cm). Number to be randomised: 1500 |
Interventions | Patients are randomized to 1 of 3 treatment arms. See Table 4. |
Outcomes | PFS, OS, adverse events and QOL |
Starting date | Aug 2009 |
Contact information | Joan Walker USA 405‐271‐8707 |
Notes |